Table 2 Context of the first referral to the integrated oncology and palliative care program (IOPC), relatively to the course of disease and project of care
From: First referral to an integrated onco-palliative care program: a retrospective analysis of its timing
N | % | |
|---|---|---|
(*total number of subjects specified in the case of missing data) | (or median) | (or Q1-Q3) |
Stage of disease(*n = 414) | ||
At diagnosis | 110 | 26,6 |
Stability of tumour or positive response to last treatment | 34 | 8,2 |
Tumour progression | 270 | 65,2 |
Antitumoral treatment use at the moment of 1st OPM(*n = 413) | ||
Treatment on course | 222 | 53,8 |
Treatment to come or 1st line not yet evaluated | 92 | 22,3 |
No treatment considered | 29 | 7,0 |
Treatment definitely discontinued | 70 | 16,9 |
Setting of care at the moment of 1st OPM(*n = 406) | ||
Inpatient care | 150 | 36,9 |
Ambulatory / Outpatient clinic | 256 | 63,1 |
Individual prognostic factors | ||
ECOG-Performance status (PS) (*n = 397) | ||
≤ 2 | 221 | 55,7 |
≥ 3 | 176 | 44,3 |
Serum albumin level, g/L (*n = 358) median (Q1-Q3) | 34 | (29–38) |
≥ 35 | 164 | 45,8 |
28–34 | 125 | 34,9 |
< 28 | 69 | 19,3 |
Serum C-reactive protein level, g/L (*n = 353) median (Q1-Q3) | 40 | (13–85) |
> 5 | 308 | 87,3 |
≤ 5 | 45 | 12,7 |
Serum Lymphocytes level, /mm3(*n = 372) median (Q1-Q3) | 1135 | (800–1603) |
≥ 1500 | 111 | 29,8 |
700–1500 | 194 | 52,2 |
< 700 | 67 | 18,0 |
Serum Lactate Dehydrogenase level, UI/L (*n = 156) median (Q1-Q3) | 441 | (339–670) |
≥ 400 | 93 | 59,6 |
< 400 | 63 | 40,4 |